MAManuel Alanís-Bernal

Manuel Alanís-Bernal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Manuel Alanís-Bernal has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Standardized Ultrafast Transcranial Ultrasound Acquisition in Acute Stroke: The HYPER‐AI‐SCAN Pilot Study With Exploratory Artificial Intelligence Analysis

    by Renato Simonetti, Jesús David González Riveros, Pere Canals, Manuel Alanís‐Bernal, Julia Fernandez Martinez, Laia Boada Oller, Olalla Pancorbo, Noelia Rodriguez‐Villatoro, Ane Murillo‐Olaizola, Álvaro García‐Tornel, et al.

    Background: Intracerebral hemorrhage requires rapid mechanism‐specific treatment, yet early stroke triage relies on clinical severity scales that do not reliably distinguish hemorrhage from ischemic stroke. We assessed the feasibility of a standardized ultrafast transcranial ultrasound protocol designed to support subsequent artificial intelligence (AI)‐based intracerebral hemorrhage detection. Methods: HYPER‐AI‐SCAN (Hyper‐Acute AI‐Assisted Sonographic Cerebral Hemorrhage Assessment Network) was a single‐center prospective feasibility study with embedded exploratory AI analysis. Between March and December 2025, 102 adults with acute computed tomography (CT)‐confirmed stroke were prospectively enrolled according to trained operator availability. Primary feasibility outcomes were protocol completion, operator‐rated adequate transtemporal windows, and acquisition time. In patients with retrievable paired baseline CT, exploratory AI analyses compared CT‐only, ultrasound‐only, and cross‐modal CT‐guided ultrasound models using patient‐level area under the receiver operating characteristic curve, sensitivity, and specificity. Results: Two patients were excluded after acquisition because insonation depth was <19 cm, yielding 100 evaluable patients (33 intracerebral hemorrhage; 67 ischemic stroke). The protocol was completed in all evaluable patients; adequate transtemporal windows were identified in 87%, and median acquisition time was 22 seconds (interquartile range, 13–31). Paired baseline CT images were available in 91 patients. Mean area under the receiver operating characteristic curve was 0.86 (SD, 0.07) for the CT‐only model, 0.85 (SD, 0.14) for the ultrasound‐only model, and 0.92 (SD, 0.07) for the cross‐modal model. Conclusions: Standardized ultrafast transcranial ultrasound acquisition was feasible at the bedside in acute stroke and generated brief cine‐loops suitable for exploratory AI development. Multicenter external validation is required before diagnostic or triage application. Registration Information: Clinicaltrials.gov. Identifier: NCT07319013.

  • Long‐term mortality after status epilepticus: A 5‐year analysis study

    by Manuel Alanís‐Bernal, Daniel Campos‐Fernández, Laura Abraira, Laura Gómez‐Dabó, Marc Rodrigo‐Gisbert, Manuel Quintana, Sofía Lallana, Elena Fonseca, Samuel López‐Maza, Manuel Toledo, et al.

    Objective: To describe 5‐year mortality after status epilepticus (SE) and identify factors associated with long‐term survival. We also validated the prognostic performance of the Age, Consciousness, Duration (ACD) score and evaluated long‐term survival across etiological categories defined by the Lattanzi classification of acute symptomatic SE. Methods: Retrospective cohort analysis of a prospectively maintained database of consecutive patients ≥16 years of age with confirmed SE admitted to a tertiary epilepsy center (2011–2022). We excluded unclear diagnoses, hypoxic–anoxic etiologies, and incomplete follow‐up. We recorded clinical variables and prognostic scores modified Status Epilepticus Severity Score (mSTESS), Epidemiology‐based Mortality Status Epilepticus (EMSE), and Age, Consciousness, Duration (ACD). Mortality was assessed at discharge and annually up to 5 years. Results: We included 786 patients (mean age 63.4 years, 43.5% female). Five‐year mortality was 50.3%, with 44.0% of deaths occurring within the first 2 years. Neurological causes accounted for 60.8% of deaths, and direct seizure‐related causes represented 74.6% of neurological deaths. Independent predictors of higher long‐term mortality were older age, higher premorbid mRS, absence of prior seizure history, comorbidity burden, systemic complications, and impaired consciousness during SE; convulsive and focal motor SE were associated with lower mortality risk. mSTESS and EMSE were associated with long‐term mortality. In patients with less damaging etiologies, ACD predicted 5‐year mortality (hazard ratio [HR] 1.163, 95% confidence interval [CI] 1.063–1.273; area under the curve [AUC] 0.717); ACD ≥10 corresponded to >50% 2‐year mortality. Five‐year mortality was 61.3% (acute‐primary Central Nervous System (CNS) and 58.3% (acute‐secondary CNS). Significance: SE carries substantial long‐term mortality, particularly within the first 2 years. Neurological and seizure‐related causes were the most frequent. The Lattanzi classification and the ACD score retained long‐term prognostic value.

  • Delirium in critically ill patients treated with levetiracetam or brivaracetam: a comparative study

    by Manuel Alanís-Bernal, Anna Sánchez, Laura Doménech-Moral, Manuel Quintana, Laura Abraira, Elena Fonseca, Samuel López-Maza, María Garcés-Pellejero, Enric Bellido-Castillo, Estevo Santamarina, et al.

  • Development of a deep learning tool to detect drug-resistance epilepsy with EEG

    by Manuel Alanís-Bernal, José Ramón Vélez-Rodríguez, Daniel Campos-Fernández, Manuel Quintana, Laura Abraira, Elena Fonseca, Samuel López-Maza, Sofia Lallana, María Garcés-Pellejero, Enric Bellido-Castillo, et al.

  • Characterization of neuropsychiatric symptoms in patients with early-stage Alzheimer’s disease in a specialized outpatient clinic

    by Manuel Alanís-Bernal, Laura Melgarejo, Laia Boada-Oller, Santiago Rios, Olga Maisterra, Alejandro Ballvé, Mariateresa Buongiorno, Darly Giraldo, Pilar Delgado, Belén Gutiérrez, et al.

    Objective To describe the frequency and temporal onset of neuropsychiatric symptoms (NPS) around the diagnosis of Alzheimer’s disease (AD) and to explore their associations with clinical and paraclinical variables. Methods We conducted a retrospective observational study of patients diagnosed with AD between 2020 and 2024, including NPS emerging from six years before to four years after diagnosis. Symptoms were classified by temporal onset as preNPS or postNPS and categorized into affective, psychotic, and behavioral domains. Clinical and demographic data, cerebrospinal fluid (CSF) biomarkers, and FDG-PET imaging findings were collected. Results Among 184 patients (mean age 76.7 ± 9.0 years; 68% female), preNPS occurred in 78.2% and postNPS in 53.8%. Psychotic preNPS were associated with older age (81.4 ± 8.6 vs. 76.3 ± 8.9 years; p = 0.049), lower Mini-Mental State Examination scores (19.9 ± 3.7 vs. 22.1 ± 4.1; p = 0.033), and use of benzodiazepines (38.5% vs. 14.0%; p = 0.036) and antipsychotics (61.5% vs. 7.0%; p < 0.001). Affective preNPS were more common in women (71.9% vs. 55.4%; p = 0.029) and were associated with antidepressant use (p < 0.001) and lower alcohol intake (p = 0.018). Behavioral preNPS predominated in men (57.1% vs. 30.1%; p = 0.013) and were associated with a greater preservation of temporal lobe metabolism in FDG-PET imaging (28.0% vs. 76.2%; p = 0.04). PostNPS correlated with disease duration (r = 0.19; p = 0.01) and higher CSF total tau levels (386.9 ± 112.8 vs. 347.1 ± 148.9; p = 0.04). Conclusion NPS are frequent in early-stage AD, with psychotic preNPS linked to older age and greater cognitive decline, and postNPS correlating with disease duration and CSF tau, indicating an association with neurodegeneration.